Your Clients Are on the Weight-Loss Jab. Here's the Muscle Problem — and Exactly How to Coach It.

How we sourced this. Every claim below is tied to a named study — a randomised trial, a meta-analysis, a body-composition substudy, or the live trial registry — and linked. We also graded the evidence: where it’s strong, we say so; where it’s early or still being tested, we say that too. GLP-1 medications are prescription drugs managed by a doctor — everything here is coaching information about training and nutrition alongside them, not medical or dosing advice. Last updated 24 July 2026.

The question every coach is about to get

A meaningful share of your clients are on a GLP-1 drug — semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro) — or they’re about to ask you about one. The weight is coming off faster than anything you’ve seen from a diet, and the internet is split down the middle: one camp says these drugs are a miracle, the other says they’ll “waste your muscle away.” As usual, the useful truth is in between, and knowing exactly where is a genuine edge you can offer.

So we pulled the body-composition trials, the reviews, and the registry, graded them, and worked out what a coach should actually do. Here’s what holds up — written so you can use it with a client on the drug today, not so you can pass an endocrinology exam.

One framing up front: the drug handles the fat loss. Your job is to protect the muscle underneath it. That division of labour is the entire article.

How much muscle is actually lost

Start with the number, because it’s real. When researchers put people on tirzepatide and measured body composition by DXA, roughly 75% of the weight lost was fat and about 25% was lean mass — a split that held across sex, age, and how much weight people lost.² A network meta-analysis pooling 22 randomised trials landed in the same place: GLP-1-class drugs reduced lean mass by around 0.86 kg on average, about a quarter of total weight lost.¹

In absolute terms that adds up. Reviews of the longer trials put the muscle loss at roughly 6 kg, about 10% of lean mass, over 68–72 weeks — an amount comparable to 10 to 20 years of normal age-related muscle loss, compressed into a year and a half.⁴⁵ That’s not nothing, and for the wrong client it’s a real problem.

Evidence grade: strong on the quantity. Multiple RCTs and a meta-analysis agree that roughly a quarter of GLP-1 weight loss is lean mass.

The nuance that defuses half the panic

Here’s what the scaremongering leaves out, and it’s the part that makes you sound like you actually read the studies. That 25% lean split is roughly what happens in any substantial weight loss — placebo dieters in the same trials lost a similar proportion of lean mass. Losing weight has always cost some lean tissue; these drugs didn’t invent that, they just made the weight loss bigger and faster.

Two more honest caveats. First, “lean mass” on a DXA is not the same as “muscle” — it includes water, organ tissue, and connective tissue, and reviews argue a good chunk of the change is adaptive (your body needs less tissue to carry a lighter frame) rather than pathological wasting.³ Second, the alarming social-media claims often point to a pharmacovigilance “muscle atrophy” signal — a disproportionality analysis of adverse-event reports found more muscle-atrophy reports for semaglutide (reporting odds ratio 2.39) — but that’s a hypothesis-generating signal, explicitly not proof the drug causes it.⁸

So “Ozempic melts your muscle” is overstated. The accurate version is quieter and more useful: this is normal weight loss, accelerated — and like all weight loss, it costs some muscle unless you actively defend it.

Evidence grade: strong that the lean split mirrors ordinary weight loss; early on how much of the change is truly muscle versus adaptive tissue.

Function often holds — so coach to strength, not the scale

This is the finding that should reshape how you talk to a client about it. Despite lean mass dropping on the scan, strength and function frequently hold steady or even improve. In a prospective cohort on semaglutide, grip strength rose by about 4.5 kg over a year, and the share of people with sarcopenic obesity fell from 49% to 33% — because they were also shedding the fat that was dragging their function down.⁶ Reviews describe the same pattern of preserved or improved muscle quality even as raw lean mass falls.³

The coaching implication is clean: a falling DXA number can look scary while the client is getting objectively stronger and more mobile. If you anchor them to a strength metric instead of the lean-mass readout, you keep them focused on the thing that actually matters for their life — and you stop a scary scan from derailing an otherwise successful process.

Evidence grade: early-to-moderate. The function data are mostly single-arm or observational, so treat “strength holds” as encouraging and likely, not guaranteed for everyone.

The fix: lift and eat protein (and yes, this part is on you)

Now the actionable core, and the good news is you already own both levers. Resistance training in a calorie deficit is the strongest defence: supervised programmes have added roughly 3 kg of lean mass and about 25% strength even while people were losing weight.⁴ Pair that with protein — expert consensus recommends at least 1.2 g/kg/day during rapid weight loss, and higher protein intake preserved lean tissue in dieting older adults.⁷⁵ This matters double on a GLP-1 drug, because the appetite suppression quietly tanks protein intake exactly when it’s most needed.

The honest caveat that keeps you credible: most of this evidence comes from weight-loss trials in general, not head-to-head studies during semaglutide or tirzepatide specifically. Those trials — resistance training vs protein vs both, on the drug — are largely still recruiting, not finished.⁹ So the mechanism is sound and the recommendation is safe and standard, but tell clients it’s “the best-evidenced plan we have,” not “proven on your exact medication.”

Evidence grade: strong that lifting + protein protect lean mass in a deficit; early for the GLP-1-specific head-to-head proof.

What’s being tested next

Here’s the live edge, and it’s moving fast. The registry now lists a large and growing pipeline of trials pairing GLP-1 drugs with exercise and protein — including the four-arm LEAN-PREP trial (control vs resistance exercise vs protein vs both, measuring quadriceps muscle by MRI) and university programmes testing strength training and protein supplementation directly on people taking these medications.¹⁰ Within a year or two we’ll have real answers on exactly how much muscle a good training-and-protein plan saves on these drugs. Being the coach who understood the question before the answers land is how you earn the client who just started their first injection. We’ll update this piece as those read out — that’s the point of an evidence page that’s alive instead of frozen.

Your script for Monday

When a client tells you they’ve started a weight-loss jab, here’s the whole thing in plain language:

“Great — the drug will handle the fat loss. My job is to make sure what comes off is fat, not muscle, because about a quarter of any weight loss is muscle unless you fight for it. So two non-negotiables: we lift at least a couple of times a week, and you hit your protein — roughly 1.2 to 1.6 grams per kilo a day, which is hard because the drug kills your appetite, so we’ll plan it. Don’t panic if a body scan says your ‘muscle’ dropped; we’re going to track your actual strength, and that usually holds or goes up. Keep your doctor in the loop on the medication side — I handle the training and the food.”

That’s it. No miracle-drug hype, no muscle-wasting panic, no overpromising. Just the evidence, translated into something a human can act on — which is the entire job.

Sqwod reads the research so your clients don’t have to. This is coaching information about training and nutrition, not medical advice; GLP-1 medications are prescription drugs and all dosing, side-effect, and health decisions belong with the prescribing doctor. Spotted something that needs sharpening? That’s how an evidence page stays honest — tell us and we’ll correct it in public.